



Relapsing Fever in 
Traveler Returning 
from Senegal
To the Editor: Although tick-
borne relapsing fever (TBRF) may 
be caused by ≈20 Borrelia species 
(1), it is rarely diagnosed in travelers 
returning from the tropics (2). 
Approximately 20 travel-related 
cases have been published in the 
past 25 years, and most of them 
have been acquired in western Africa 
(mainly Senegal), where Borrelia 
crocidurae is the predominant 
species (3). All reported cases have 
been diagnosed by identifi cation 
of spirochetes in blood smears or 
by quantitative buffy coat analysis. 
Neurologic involvement, which is 
frequent in TBRF (4), was reported 
for 3 confi rmed travel-associated 
cases (5–7) and for 2 additional 
clustered cases not confi rmed by 
microscopy (8). We report a case 
of acute meningoencephalitis in a 
returning traveler for whom TBRF 
was diagnosed by only PCR of serum 
and cerebrospinal fl uid (CSF).
In December 2010, a 26-year-old 
Belgian woman was referred to the 
intensive care unit of the University 
Hospital of Antwerp, Belgium, 
because of fever and headache 
for 7 days and abrupt neurologic 
deterioration the day before 
admission. One month earlier, she had 
returned from a 3-week adventure trip 
to a rural area near Bambey, 120 km 
east of Dakar, Senegal. Immunization 
and malaria chemoprophylaxis had 
been appropriate. Diarrhea and fever 
developed the day she returned. 
She was empirically treated with 
ofl oxacine for 5 days and recovered.
At admission, she reported 
high-grade fever, headache, and 
photophobia. She was somnolent, 
inadequate in her answers, and had neck 
stiffness. Laboratory investigations 
showed a leukocyte count of 20 × 
109 cells/L (82% neutrophils) and 
a C-reactive protein level of 190 
mg/L. Blood smears were repeatedly 
negative. Magnetic resonance imaging 
of the brain showed no abnormalities. 
CSF contained 350 leukocytes/mm3 
(95% lymphocytes) and had a protein 
level of 125 mg/dL.
Acyclovir, ceftriaxone, ampicillin, 
and doxycycline were empirically 
administered. A rash developed 
abruptly, and the patient became 
hypotensive and extremely agitated. 
Treatment with ampicillin was stopped 
because of a suspected allergic reaction. 
Blood and CSF cultures remained 
negative. Results of molecular testing of 
CSF for herpesvirus and enteroviruses 
were negative.
The patient recovered unevent-
fully after a 14-day course of 
ceftriaxone. Paired serologic 
samples did not show seroconversion 
for HIV, Treponema pallidum, 
cytomegalovirus, dengue virus, 
West Nile virus, Toxoplasma gondii, 
Rickettsia spp., Coxiella burnetii, 
Leptospira sp., and B. burgdorferi.
At the Université de la 
Méditerranée in Marseille, France, 
DNA samples from CSF and 
acute-phase and convalescent-
phase serum samples were tested 
by using quantitative real-time 
PCR specifi c for a fragment of 
the 16S rRNA gene of Borrelia 
spp. (9). Borrelia-positive results 
were confi rmed by using Borrelia-
specifi c quantitative PCR specifi c 
for the internal transcribed spacer 






An amplicon of 202 bp was 
obtained from a CSF DNA sample after 
amplifi cation and sequencing of the 
fl agellin B gene with primer set Bfpbu: 
5 ′ - G C T G A A G A G C T T G G A AT
GCAACC-3′ and Bfpcr: 5′-TGATCA
GTTATCATTCTAATAGCA-3′. This 
amplicon showed 100% similarity with 
sequences available in GenBank for B. 
crocidurae (accession no. GU357619). 
Indirect immunofl uorescence with B. 
crocidurae antigen showed positive 
bands for IgM and IgG (Table).
B. crocidurae has emerged as 
a major zoonotic pathogen in rural 
western Africa and accounts for 5%–
25% of febrile illnesses depending 
on year and location (3,9,10). 
Transmission occurs through nocturnal 
bites of soft ticks (Ornithodoros 
sonrai), which colonize rodent burrow 
openings in mud-built huts and houses 
with cement fl oors (1). Therefore, 
TBRF should be considered in any 
symptomatic traveler in disease-
endemic areas.
We identifi ed B. crocidurae 
DNA in the CSF of a patient with 
meningoencephalitis complicating 
relapsing fever. Meningitis and 
meningoencephalitis may develop 
in persons with travel-related TBRF 
(5–8). The neurologic outcome 
was favorable after treatment with 
ceftriaxone for 14 days (4), and 
relapse was not observed. Negative 
blood smears, even when repeated 
and read by laboratory experts, do 
not rule out TBRF. Recent studies 
have demonstrated that sensitivity of 
blood smear examination performed 
by trained microscopists does not 
exceed 50% compared with PCR 
methods (9) and is much lower in fi eld 
settings (9,10). Abrupt deterioration 
(rash, hypotension, and increased 
encephalopathy) after treatment with 
antimicrobial drugs was probably 
related to a Jarish-Herxheimer reaction 
(4). This reaction was not immediately 
considered but was easily controlled by 
supportive treatment in the intensive 
care unit. The noninvestigated episode 
of fever upon return of the patient may 
have been the initial fever episode of 
TBRF, but it was lessened by the short 
course of ofl oxacine (4). Absence of 
laboratory workup could have caused 
serious infections to be missed.
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In conclusion, this case 
indicates an unusual complication 
and condition in travel medicine 
with no straightforward diagnosis. 
However, it illustrates that TBRF 
should be systematically considered 
in the differential diagnosis of acute 
meningoencephalitis in travelers, even 
if microscopic results are negative, 
to prompt appropriate empirical 
treatment and molecular or serologic 
testing.
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To the Editor: Since 1999, 
several exanthematous vaccinia virus 
(VACV) outbreaks affecting dairy 
cattle and rural workers have been 
reported in Brazil (1,2). VACV, the 
prototype of the genus Orthopoxvirus 
(OPV), exhibits serologic cross-
reactivity with other OPV species and 
was used during the World Health 
Organization smallpox eradication 
campaign (3). The origin of VACV 
in Brazil is unknown, although some 
studies have suggested that VACV 
strains used during the campaign 
may be related to outbreaks of bovine 
vaccinia (BV) (2). In Brazil, BV affects 
the milk industry and public health 
services (1,2,4,5). During outbreaks, 
dairy cattle developed lesions on the 
teats and udders, causing a decrease in 
milk production (1,2,4,5). 
Another VACV subspecies, 
buffalopox virus (BPXV), has been 
isolated from buffaloes (Bubalus 
bubalis) in rural areas in India and 
causes clinical signs that resemble 
those seen during BV outbreaks in 
Brazil (6). Recent genetic analysis of 
BPXV samples confi rmed its close 
relationship to VACV-like viruses, 
although each virus has distinct 
genetic signatures (1,2,6). Until 
recently, buffalo herds have been 
almost exclusive to northern Brazil. 
However, the buffalo market has 
experienced great expansion in this 
country, and today, there are herds 
in all geographic regions of Brazil. 
These buffalo herds are hypothetically 
at risk for VACV infection, on the 
basis of the outbreaks caused by 
BPXV that have been described in 
India (6). To assess the risk for OPV 
infection in milk buffaloes in Brazil, 
we conducted a serosurvey of herds 
from southeastern Brazil, the region 
most affected by BV.
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Table. Test results for 26-year-old woman who returned to Belgium from Senegal with 
meningoencephalitis complicating relapsing fever* 
Characteristic
Date and test result 
2010 Dec 21 2011 Jan 25 
Borrelia DNA in serum + for 16S rRNA and ITS4 genes – 
Borrelia DNA in CSF + (100% similarity to B. crocidurae flaB gene; 
GenBank accession no. GU357619) 
B. crocidurae IgM titer 25 0 
B. crocidurae IgG titer 400 400 
B. dutonii IgM titer 0 0 
B. dutonii IgG titer 200 200 
B. recurrentis – – 
B. burgdorferi – – 
*+, positive; ITS, internal transcribed spacer; –, negative; CSF, cerebrospinal fluid; fla, flagellin. 
